SMT. HANSA MEHTA LIBRARY
The M. S. University of Baroda

INDEX

TITLES	Page No.
Contents	I-IX
List of Tables	X-XI
List of Figures	XII-XIV
CHAPTER I **1. INTRODUCTION**	1-8
1.1 General	1
1.2 Aims and Objective	6
Reference	7
CHAPTER II **2. LITERATURE REVIEW**	9-94
2.1 Solid lipid Nanoparticles	9
2.1.1 Introduction	9
2.1.2 Formulation of SLNs	11
2.1.2.1 High pressure homogenization (HPH)	11
2.1.2.2 Microemulsion technique	14
2.1.2.3 Solvent emulsification-evaporation or diffusion method	15
2.1.2.4 Solvent Injection Method	15
2.1.2.5 w/o/w double emulsion method	16
2.1.3 Characterization of SLNs	16
2.1.3.1 Particle characterization	17
2.1.3.2 Crystallinity and polymorphic nature	18
2.1.3.3 Structure of SLNs and drug distribution	19
2.1.3.4 Encapsulation efficiency and drug loading capacity	20
2.1.3.5 *In vitro* release	21
2.1.4 Applications of SLNs	22
2.1.4.1 Parenteral administration	22
2.1.4.2 Oral administration	23
2.1.4.3 Topical application	23
2.1.5 Commercialization of SLNs	24
2.1.6 Current and Future Developments	25
2.2 Nanosuspension	27
2.2.1 Introduction	27
2.2.2 Formulation Theory	30
2.2.3 Manufacturing of nanosuspension	33
2.2.3.1 Pearl milling (wet milling)	34
2.2.3.2 High pressure homogenization	37
2.2.4 Formulation considerations	39

2.2.4.1 Organic solvents	39
2.2.4.2 Stabilizers	39
2.2.4.3 Co-surfactants	40
2.2.4.4 Other additives	41
2.2.5 Characterization of Nanosuspensions	41
2.2.5.1 Mean particle size and particle size distribution	42
2.2.5.2 Particle charge (Zeta Potential)	44
2.2.5.3 Crystallinity and polymorphism	45
2.2.5.4 Saturation solubility and dissolution velocity	46
2.2.5.5 Electron Microscopy	47
2.2.5.6 In vitro release	49
2.2.6 Applications of Nanosuspension	50
2.2.6.1 Oral drug delivery	51
2.2.6.2 Parenteral drug delivery	53
2.2.6.3 Ocular drug delivery	54
2.2.6.4 Pulmonary drug delivery	55
2.2.7 Products on the market/in clinical phases	56
Reference	60
DRUG PROFILES 2.3 Saquinavir	77
2.3.1 Description	77
2.3.2 Analytical method	78
2.3.3 Clinical Pharmacology	78
2.3.4 Indications and Usage	81
2.3.5 Adverse events / Toxicity	82
2.3.6 Contraindications	82
2.3.7 Dosage and Administration	82
2.3.8 Adults (Over the Age of 16 Years)	83
2.3.9 Storage	83
2.3.10 Prior work done	83
2.4 Adefovir Dipivoxil	86
2.4.1 Description	86
2.4.2 Mechanism of action	86
2.4.3 Antiviral Activity	87
2.4.4 Contraindications	88
2.4.5 Adverse effects	88
2.4.6 Indications	88
2.4.7 Dosage and administration	88
2.4.8 Prior work done	89
References	91

CHAPTER III 3. ANALYTICAL METHOD	95-115
3.1 MATERIALS	95
3.2 Estimation of Saquinavir by Ultraviolet Spectrophotometry (UV)	95
3.2.1 Calibration Curve	95
3.2.2 Analytical method validation	96
3.2.2.1 Linearity	96
3.2.2.2 Accuracy	96
3.2.2.3 Precision	97
3.2.3 Results and Discussion	97
3.3 Estimation of Adefovir Dipivoxil by Ultraviolet Spectrophotometry (UV)	104
3.3.1 Calibration Curve	104
3.3.2 Analytical method validation	105
3.3.3 Results and Discussion	105
References	114
Chapter IV 4. Formulation Devlopment of Saquinavir Solid Lipid Nanoparticles	116-139
4.1Materials	116
4.1.1 Equipments	116
4.2 Partition coefficient study	117
4.3Preparation of Saquinavir loaded SLNs (SQSLN)	117
4.4Optimization of Parameters	118
4.4.1 Process parameter	118
4.4.1.1 Homogenization Cycles	118
4.4.2 Formulation parameters	118
4.4.2.1 Type of emulsifier	118
4.4.2.2 Concentration of emulsifier	118
4.4.2.3 Concentration of Saquinavir (w.r.t. lipid)	118
4.5 Characterization	118
4.5.1 Particle size analysis	118
4.5.2 Zeta Potential	119
4.5.3 Entrapment efficiency	119
4.5.4 Solid State Studies	119

4.5.4.1 Differential Scanning Calorimetry (DSC) study	119
4.5.4.2 XRD Studies	119
4.5.4.3 Transmission electron microscopy	119
4.5.4.4 In vitro release study	119
4.5.4.5 Stability Study	120
4.5.4.6 GI stability study (acid stability study)	120
4.6 Results and Discussion	120
4.6.1 Partition coefficient study	120
4.6.2 Optimization of Parameters	121
4.6.2.1 Process parameter	121
4.6.2.1.1 Homogenization Cycles	121
4.6.2.2 Formulation parameters	122
4.6.2.2.1 Selection of emulsifier	122
4.6.2.2.2 Concentration of emulsifier	123
4.6.2.2.3 Concentration of Saquinavir (w.r.t. lipid)	125
4.6.3 Differential Scanning Calorimetry (DSC)	126
4.6.4 X ray diffraction study	128
4.6.5 Transmission electron microscopy (TEM)	130
4.6.6 In vitro release	131
4.6.7 Stability Study	133
4.6.7.1 Short term stability study	133
4.6.7.2 Long term	134
4.6.7.2.1 Samples stored at 2 – 8 ^{0}C	134
4.6.7.2.2 Samples stored at RT	136
4.6.8 GI stability study	138
Reference	139
Chapter V 4. Formulation Development of Saquinavir Nanosuspension	140-160
5.1 Materials	140
5.2 Methods	140
5.2.1 Preparation of Saquinavir Nanosuspension (SNS)	140
5.2.2 Preparation of Saquinavir suspension (SQSV)	140
5.2.3 Optimization of parameters	141
5.2.3.1 Milling time	141

5.2.3.2 Ratio of beads	141
5.2.3.3 Selection of surfactant	141
5.2.4 Optimization by Factorial designs	141
5.2.5 Lyophilization of Nanosuspension	143
5.2.6 Characterization of Nanosuspension	143
5.2.6.1 Particle Size and Zeta Potential Measurement	143
5.2.6.2 Determination of Saturation solubility	143
5.2.6.3 Assay	143
5.2.6.4 Differential Scanning Calorimetry	143
5.2.6.5 X Ray Diffractometry	143
5.2.6.6 Transmission Electron Microscopy	144
5.2.6.7 In vitro release	144
5.2.6. 8 Optimization Data Analysis	144
5.3 Results and Discussion	145
5.3.1 Optimization of Parameters	145
5.3.1.1 Milling time	145
5.3.1.2 Ratio of beads	146
5.3.1.3 Selection of surfactant	147
5.3.2 Optimization by Factorial design	148
5.3.2.1 Effect of formulation variables on the response parameters	149
5.3.2.2 Optimum Formulation	154
5.3.3 Saturation solubility	155
5.3.4 Assay	156
5.3.5 Differential Scanning Calorimetry	156
5.3.6 X Ray Diffractometry	157
5.3.7 Transmission Electron Microscopy (TEM)	157
5.3.8 In vitro release	159
Reference	160
Chapter VI 6. Radiolabelling and In vivo biodistribution of Saquinavir formulations	161-178
6.1 Introduction	161
6.2 Materials	161
6.3 Method	162
6.4 Optimization of radiolabeling of Saquinavir loaded SLN, NS and MS by direct labeling procedure	162
6.5 Stability Study of 99mTc-labeled Complexes	163
6.6 Pharmacokinetic and Biodistribution study	163

6.7 Pharmacokinetic analysis	164
6.7.1 Data analysis	165
6.8 Results and Discussion	165
6.8.1 Stability of the ^{99m}Tc labeled complexes	165
6.8.2 Cysteine, Histidine and DTPA challenge tests	165
6.8.3 Pharmacokinetic and Biodistribution study	167
6.8.4 Biodistribution Study	171
References	178
Chapter VII **7. Formulation Development of Adefovir Dipivoxil Solid lipid Nanoparticles**	179-203
7.1 Materials	179
7.1.1 Equipments	179
7.2 Partition coefficient study	180
7.3 Preparation Of Adefovir Dipivoxil Loaded SLN	180
7.4 Optimization Of Parameters	181
7.4.1 Process parameters	181
7.4.1.1 Stirring Speed	181
7.4.1.2 Stirring Time	181
7.4.2 Formulation parameters	182
7.4.2.1 Organic Solvent	182
7.4.2.2 Lipid loading	182
7.4.2.3 Selection of surfactant	182
7.4.2.4 Concentration of surfactant	182
7.4.2.5 Drug loading	182
7.5 Characterization of Formulations	183
7.5.1 Particle size analysis	183
7.5.2 Zeta Potential	183
7.5.3 Entrapment efficiency	183

7.5.4 Solid State Studies	183
7.5.4.1 DSC Thermograms	183
7.5.4.2 XRD Studies	183
7.5.5 Transmission electron microscopy	183
7.5.5 In vitro release study	183
7.5.6 Stability Study	183
7.5.7 GI stability study (acid stability study)	184
7.6 Results and Discussion	184
7.6.1 Partition coefficient study	184
7.6.2 Process parameters	184
7.6.2.1 Stirring speed	184
7.6.2.2 Stirring Time	185
7.6.3 Formulation parameters	186
7.6.3.1 Organic Solvent	186
7.6.3.2 Lipid loading	187
7.6.3.3 Selection of surfactant	188
7.6.3.4 Concentration of surfactant	189
7.6.3.5 Drug loading	189
7.6.4 Differential Scanning Calorimetry	190
7.6.5 X ray diffraction	192
7.6.6 Transmission Electron Microscopy (TEM)	194
7.6.7 In vitro release	194
7.7 Stability study	196
7.7.1 Short term	196
7.7.2 Long term	197
7.7.2.2 Samples stored at 2-8° C	197
7.7.2.2 Samples stored at RT	199
7.8 GI stability study (acid stability study)	200
References	202
Chapter VIII **8 Formulation Development of Adefovir Nanosuspension**	204-225

8.1 Materials	204
8.2 Methods	204
8.2.1 Preparation of Nanosuspension	204
8.2.2 Preparation of Adefovir Dipivoxil Suspension (AMS)	205
8.2.3 Optimization of process parameters	205
8.2.3.1 Milling time	205
8.2.3.2 Ratio of beads	205
8.2.3.3 Selection of surfactant	205
8.2.4 Optimization of formulation parameters	206
8.2.5 Characterization of Nanosuspension	207
8.2.5.1 Particle Size and Zeta Potential Measurement	207
8.2.5.2 Determination of Saturation solubility	207
8.2.5.3 Assay	207
8.2.5.4 Differential Scanning Calorimetry Study	207
8.2.5.5 XRD Studies	207
8.2.5.6 Transmission Electron Microscopy	207
8.2.5.7 In vitro release	208
8.2.5.8 Optimization Data Analysis	208
8.3 Results and Discussion	209
8.3.1 Optimization of Process parameters	209
8.3.1.1 Milling time	209
8.3.1.2 Selection of surfactant	210
8.3.1.3 Ratio of beads	211
8.3.2 Optimization of formulation parameters	212
8.3.2.1 Effect of formulation variables on the response parameters	213
8.3.2.2 Optimum Formulation	218
8.3.3 Characterization study of optimized formulation	219
8.3.4 Differential Scanning Calorimetry Study	220
8.3.5 X Ray Diffractometry study	221

8.3.6 Transmission Electron Microscopy (TEM)	222
8.3.7 In vitro release	224
Reference	225
Chapter IX **9. Radiolabelling and In vivo biodistribution of Adefovir dipivoxil formulations**	226-240
9.1 Introduction	226
9.2 Materials	226
9.3 Method	226
9.3.1 Labeling Efficiency	226
9.3.2 Optimization of radiolabeling of Adefovir dipivoxil loaded SLN, NS and MS by direct labeling procedure	227
9.3.3 Stability Study of 99mTc-labeled Complexes	227
9.3.4 Pharmacokinetic and Biodistribution study	227
9.3.5 Pharmacokinetic analysis	228
9.3.5.1 Data analysis	228
9.4 Results and Discussion	228
9.4.1 Stability of the ^{99m}Tc labeled complexes	228
9.4.2 Cysteine, Histidine and DTPA challenge tests	228
9.4.3 Pharmacokinetic study	230
9.4.4 Biodistribution Study	234
References	240
CHAPTER X **10. SUMMARY AND CONCLUSION**	241-248
Saquinavir Solid lipid Nanoparticles	241
Saquinavir Nanosuspension	243
Adefovir Dipivoxil Solid Lipid Nanoparticles	244
Adefovir Dipivoxil Nanosuspension	246
CONCLUSION	248
Appendix – 1 Presentations and Publications	249
Appendix – 2 Errata	250